SMO protein inhibitors - Pipeline Insight, 2024

SMO protein inhibitors - Pipeline Insight, 2024



DelveInsight’s, “SMO protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in SMO protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
SMO protein inhibitors Understanding

SMO protein inhibitors: Overview

SMO is a G-protein-coupled receptor (GPCR) of the Frizzled-class (class-F). It transduces the Hedgehog signal from the tumour suppressor Patched-1 (PTCH1) to the glioma-associated-oncogene (GLI) transcription factors, which activates the Hedgehog signalling pathway. Mutations in SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma. Overexpression of either Wnt-1 or the GLI proteins results in cancer. Inhibition of the Smoothened (SMO) protein prevents the induction of GLI transcriptional activity upon exposure of cancer cells to Shh ligands. Loss of induction of GLIs upon activation of Shh signaling inhibits the ability of Shh signaling to promote tumor progression. Therapies that inhibit Smo have many applications in cancer treatment, therefore several active clinical trials are going on to check efficacy.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence SMO protein inhibitors R&D. The therapies under development are focused on novel approaches for SMO protein inhibitors.
SMO protein inhibitors Emerging Drugs Chapters

This segment of the SMO protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

SMO protein inhibitors Emerging Drugs
  • GT1708F: Suzhou Kintor Pharmaceuticals
GT 1708F is a smoothened trans-membrane protein (SMO) antagonist (or Hedgehog signaling pathway inhibitor). The drug is currently in Phase I clinical studies for the treatment of leukemia and Basal Cell Carcinoma.
  • ENV-101: Endeavor BioMedicines
ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog signaling pathway that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor intends to initiate a Phase 2 study of ENV-101 as a monotherapy in patients with IPF in the second quarter of 2021.

Further product details are provided in the report……..

SMO protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different SMO protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on SMO protein inhibitors
There are approx. 8+ key companies which are developing the SMO protein inhibitors. The companies which have their SMO protein inhibitors drug candidates in the most advanced stage, i.e. Phase III, PellePharm.
  • Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
SMO protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

SMO protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses SMO protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging SMO protein inhibitors drugs.

SMO protein inhibitors Report Insights
  • SMO protein inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
SMO protein inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing SMO protein inhibitors drugs?
  • How many SMO protein inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for SMO protein inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the SMO protein inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for SMO protein inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Pfizer
  • Endeavor BioMedicines
  • PellePharm
  • Sun Pharmaceutical Industries
  • Roche
  • Guangdong Zhongsheng Pharmaceutical
  • Suzhou Kintor Pharmaceuticals
Key Products
  • Glasdegib
  • ENV-101
  • Patidegib
  • Sonidegib
  • Vismodegib
  • ZSP1602
  • GT1708F


Introduction
Executive Summary
SMO protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
SMO protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
SMO protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
SMO protein inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Patidegib: PellePharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ENV-101: Endeavor BioMedicines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
SMO protein inhibitors Key Companies
SMO protein inhibitors Key Products
SMO protein inhibitors- Unmet Needs
SMO protein inhibitors- Market Drivers and Barriers
SMO protein inhibitors- Future Perspectives and Conclusion
SMO protein inhibitors Analyst Views
SMO protein inhibitors Key Companies
Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings